A detailed history of Virtus ETF Advisers LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 5,256 shares of STOK stock, worth $68,222. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,256
Previous 5,167 1.72%
Holding current value
$68,222
Previous $69,000 7.25%
% of portfolio
0.03%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.24 - $15.92 $1,089 - $1,416
89 Added 1.72%
5,256 $64,000
Q2 2024

Aug 14, 2024

BUY
$11.03 - $17.52 $56,992 - $90,525
5,167 New
5,167 $69,000
Q3 2023

Nov 07, 2023

SELL
$3.78 - $11.99 $2,967 - $9,412
-785 Reduced 9.05%
7,893 $31,000
Q2 2023

Aug 14, 2023

SELL
$7.93 - $13.82 $26,962 - $46,988
-3,400 Reduced 28.15%
8,678 $92,000
Q1 2023

May 15, 2023

SELL
$7.65 - $10.38 $35,473 - $48,132
-4,637 Reduced 27.74%
12,078 $100,000
Q4 2022

Feb 14, 2023

BUY
$7.07 - $15.69 $47,687 - $105,829
6,745 Added 67.65%
16,715 $154,000
Q3 2022

Nov 14, 2022

BUY
$12.56 - $22.53 $942 - $1,689
75 Added 0.76%
9,970 $128,000
Q2 2022

Aug 12, 2022

BUY
$10.36 - $23.93 $13,840 - $31,970
1,336 Added 15.61%
9,895 $131,000
Q1 2022

May 16, 2022

SELL
$17.19 - $26.1 $8,784 - $13,337
-511 Reduced 5.63%
8,559 $180,000
Q4 2021

Feb 14, 2022

BUY
$18.11 - $30.72 $64,616 - $109,608
3,568 Added 64.85%
9,070 $218,000
Q3 2021

Nov 15, 2021

SELL
$23.65 - $34.44 $6,716 - $9,780
-284 Reduced 4.91%
5,502 $140,000
Q2 2021

Aug 10, 2021

BUY
$30.53 - $41.09 $12,975 - $17,463
425 Added 7.93%
5,786 $195,000
Q1 2021

May 17, 2021

BUY
$36.08 - $69.81 $3,499 - $6,771
97 Added 1.84%
5,361 $208,000
Q4 2020

Feb 12, 2021

BUY
$33.62 - $61.93 $176,975 - $325,999
5,264 New
5,264 $326,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $512M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.